| Nov 15 |
Analyst Estimates: Here's What Brokers Think Of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Report
|
| Nov 13 |
SpringWorks Therapeutics Inc (SWTX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Nov 12 |
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
|
| Nov 12 |
SpringWorks Therapeutics’ mirdametinib shows efficacy in neurofibromatosis study
|
| Nov 12 |
SpringWorks Therapeutics gives mixed Q3 results
|
| Nov 12 |
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
|
| Nov 11 |
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology
|
